Blueprint Medicines Corporation (NASDAQ: BPMC), a US-based global precision therapy company that said it invents life-changing therapies for people with cancer and blood disorders, announced on Tuesday that the US Food and Drug Administration (FDA) has withdrawn a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.
The company announced on 10 February 2023 that the FDA had placed a partial clinical hold on the VELA trial because of reported visual adverse events, which included transient, reversible episodes of light sensitivity and blurred vision, observed in a limited number of patients. Subjects already enrolled in the trial have continued receiving the study drug.
With the removal of the partial clinical hold, the company is working with trial sites to reinitiate patient enrolment.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval